Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
AssigneeNovelion Therapeutics Inc.
InventorSuzanne Cadden
Life of this patent
Estimating the term…
Abstract
Disclosed herein are therapeutic regimens for improving visual function in Retinitis Pigmentosa and other visual disorders associated with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative, for example a 9- or 11-cis retinyl ester, according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.
Claims29
A method of improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal comprising:
- a. administering a first therapeutic dose of a synthetic retinal derivative to a subject in need thereof, wherein the first therapeutic dose is administered as a divided dose over a period of from about 2 to about 7 days;
- b. providing a resting period of from about 7 to about 28 days;
- and
- c. administering a second therapeutic dose of the synthetic retinal derivative to said subject following the end of the resting period.
3-5. (canceled)
11-39. (canceled)
42-43. (canceled)
A kit for improving visual function in a subject having a deficiency in endogenously produced 11-cis retinal, the kit comprising,
- a. at least a first therapeutic dose of a 9- or 11-cis-retinyl ester;
- and,
- b. instructions for use that direct that the first therapeutic dose is administered as a divided dose over a period of from about 2 to about 7 days and that provides a resting period between the first therapeutic dose and a second dose, wherein the resting period is from about 7 to about 28 days.
A dosing regimen for improving visual function of a subject having a deficiency in endogenously produced 11-cis retinal, wherein the dosing regimen comprises at least, a first therapeutic dose, a second therapeutic dose and a resting period between the first therapeutic dose and the second therapeutic dose, the regimen comprising;
- a. administering a first dose of a 9- or 11-cis-retinyl ester over a period of from about 2 to about 7 days to a subject in need thereof;
- b. providing a resting period of from about 7 to about 28 days between the first therapeutic dose and the second therapeutic dose;
- and
- c. administering the second therapeutic dose of a 9- or 11-cis-retinyl ester following the end of the resting period to the subject in need thereof.
49-135. (canceled)
137-143. (canceled)
146-157. (canceled)
159-163. (canceled)
165-171. (canceled)
173-190. (canceled)
Dependencies are inferred from the claim text.